Nestlé
Nestlé Invests $200m More In Aimmune After Peanut Allergy Drug Approval

Aimmune Therapeutics Inc said on Wednesday the health science arm of Nestlé SA will invest an additional $200 million in the drugmaker, bringing the...
Investors Find Some Unilever Foods Hard To Swallow
Six months after Unilever's Alan Jope suggested he may get rid of brands without "purpose", investors are wondering when he will deliver. Thei...
Advertisement
Copyright © 2025. All rights reserved. Developed by Square1 and powered by PublisherPlus.com